Investors Purchase Large Volume of Call Options on Takeda Pharmaceutical (TAK)

Takeda Pharmaceutical Co Ltd (NYSE:TAK) was the target of some unusual options trading activity on Thursday. Stock investors purchased 5,886 call options on the company. This is an increase of approximately 3,673% compared to the average volume of 156 call options.

A number of hedge funds have recently modified their holdings of TAK. First Hawaiian Bank bought a new stake in Takeda Pharmaceutical during the 1st quarter valued at $35,000. Dubuque Bank & Trust Co. bought a new position in shares of Takeda Pharmaceutical in the first quarter worth $41,000. Dumont & Blake Investment Advisors LLC bought a new position in shares of Takeda Pharmaceutical in the first quarter worth $230,000. Neville Rodie & Shaw Inc. bought a new position in shares of Takeda Pharmaceutical in the first quarter worth $475,000. Finally, Contravisory Investment Management Inc. bought a new position in shares of Takeda Pharmaceutical in the first quarter worth $28,000. 4.42% of the stock is currently owned by institutional investors and hedge funds.

A number of equities research analysts have issued reports on TAK shares. Zacks Investment Research raised shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating and set a $23.00 target price on the stock in a report on Wednesday, March 13th. Goldman Sachs Group reissued a “buy” rating on shares of Takeda Pharmaceutical in a report on Tuesday, March 19th. Finally, ValuEngine cut shares of Takeda Pharmaceutical from a “hold” rating to a “sell” rating in a report on Wednesday.

TAK stock traded up $0.15 during midday trading on Friday, reaching $17.53. 103,486 shares of the company’s stock traded hands, compared to its average volume of 2,650,255. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.22 and a quick ratio of 2.81. Takeda Pharmaceutical has a 52 week low of $15.50 and a 52 week high of $21.95. The stock has a market capitalization of $28.17 billion, a price-to-earnings ratio of 16.38, a PEG ratio of 62.15 and a beta of 0.66.

WARNING: This story was originally posted by Transcript Daily and is the property of of Transcript Daily. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://transcriptdaily.com/2019/05/17/investors-purchase-large-volume-of-call-options-on-takeda-pharmaceutical-tak.html.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.

Featured Story: How is diluted EPS different from basic EPS?

Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.